ACHV

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company based in Vancouver, focused on developing innovative solutions to combat smoking and nicotine addiction. Its lead product, cytisinicline, has demonstrated efficacy in promoting smoking cessation, supported by robust clinical trial data. By addressing the urgent public health challenge of tobacco dependence, Achieve aims to significantly improve patient outcomes while reducing the adverse effects of tobacco use. With a commitment to advancing its therapeutic programs, Achieve Life Sciences is strategically positioned to make a lasting impact on addiction treatment both in the United States and globally.